Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Pre-Exposure Prophylaxis in YMSM

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT01033942
First received: December 16, 2009
Last updated: January 21, 2014
Last verified: August 2013

December 16, 2009
January 21, 2014
August 2009
September 2011   (final data collection date for primary outcome measure)
To evaluate the specific components of a PrEP delivery protocol that would be necessary to include in a future trial that will examine the effectiveness of PrEP as a prevention approach for YMSM at high risk for HIV infection. [ Time Frame: 28 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01033942 on ClinicalTrials.gov Archive Site
  • Examine acceptability, feasibility, and short-term reduction in sexual risk behaviors of combined bio-behavioral HIV risk reduction intervention, placebo pill control, and behavioral intervention alone. [ Time Frame: 28 weeks ] [ Designated as safety issue: No ]
  • To explore the acceptability and feasibility of PrEP as a component of a comprehensive HIV risk reduction intervention for YMSM. [ Time Frame: 28 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Pre-Exposure Prophylaxis in YMSM
Acceptability and Feasibility of a Pre-Exposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men (YMSM)

This is an exploratory mixed-methods research study that compares an efficacious behavioral HIV-prevention intervention (3MV) alone to the behavioral HIV-prevention intervention combined with a biomedical intervention (PrEP). After completing the 3MV behavioral intervention, participants will be randomly assigned to one of three study arms: 1) daily FTC/TDF as PrEP, 2) placebo pill control, or 3) "no pill" control. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks. Youth who decline to participate will be asked to complete a brief survey about their opinions on PrEP. Qualitative interviews will be completed with six study participants and the study coordinators at the end of the trial to explore further the issues of trial acceptability and feasibility. Finally, focus groups will be conducted to explore feasibility and acceptability issues with YMSM who meet all eligibility requirements of the study except for not being age 18 or older, but are at least 16 years of age.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
HIV
  • Drug: coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP
    Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
  • Drug: Placebo
    Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
  • Behavioral: Many Men, Many Voices (3MV)
    Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
  • Experimental: FTC/TDF as PrEP
    Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
    Interventions:
    • Drug: coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP
    • Behavioral: Many Men, Many Voices (3MV)
  • Placebo Comparator: Placebo Pill Control
    Blinded administration of placebo pill; HIV behavioral intervention
    Interventions:
    • Drug: Placebo
    • Behavioral: Many Men, Many Voices (3MV)
  • Active Comparator: No Pill Control
    Subjects receive HIV behavioral intervention but no pill.
    Intervention: Behavioral: Many Men, Many Voices (3MV)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
79
September 2011
September 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willing and able to independently provide written informed consent;
  • Of male gender at birth;
  • Between the ages of 18 years and 0 days through 22 years and 364 days at the time of signed informed consent;
  • Self-reporting at least one episode of unprotected anal intercourse with a male within the last 12 months at the time of PDA Screening Interview;
  • Tests HIV negative at time of screening (using any FDA-approved HIV diagnostic test);
  • Willing to provide locator information to study staff;
  • Willing to be assigned to any of the three biomedical intervention conditions;
  • Does not report intention to relocate out of the study area during the course of the study; and
  • Does not have job/other obligations that would require long absences from the area (> 4 weeks at a time).

Exclusion Criteria:

  • Transgender (behavioral intervention not targeted toward this population);
  • Presence of serious psychiatric symptoms (e.g., active hallucinations);
  • Visibly distraught at the time of consent (e.g., suicidal, homicidal, exhibiting violent behavior);
  • Intoxicated or under the influence of alcohol or other drugs at the time of consent;
  • Acute or chronic hepatitis B infection (exclude if hepatitis B surface antigen positive);
  • Renal dysfunction (Creatinine Clearance < 75 ml/min); Use Cockroft-Gault equation: GFR = (140-Age in years) x (Weight in kg) / (72 x serum creatinine) for males
  • Any history of bone fractures not explained by trauma;
  • Confirmed proteinuria (repeated positive [> 2+] urine dipstick), unless explained by orthostatic proteinuria;
  • Confirmed glucosuria (repeated positive [> 1+] urine dipstick) in the presence of normal blood glucose (<120 mg/dL);
  • Any Grade 3 toxicity on screening tests/assessments;
  • Concurrent participation in an HIV vaccine study or other investigational drug study; or
  • Known allergy/sensitivity to the study drug or its components.
  • Use of disallowed medications
Male
18 Years to 22 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01033942
ATN 082
Yes
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • National Institute on Drug Abuse (NIDA)
  • National Institute of Mental Health (NIMH)
Principal Investigator: Sybil Hosek, PhD Adolescent Trials Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
August 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP